1. Home
  2. CAC vs MLYS Comparison

CAC vs MLYS Comparison

Compare CAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

N/A

Current Price

$56.42

Market Cap

923.2M

Sector

Finance

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$23.72

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAC
MLYS
Founded
1875
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
923.2M
2.5B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
CAC
MLYS
Price
$56.42
$23.72
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
★ $59.60
$48.50
AVG Volume (30 Days)
68.8K
★ 1.2M
Earning Date
10-27-2026
11-09-2026
Dividend Yield
★ 3.04%
N/A
EPS Growth
6.08
★ 37.43
EPS
★ 2.64
N/A
Revenue
★ $41,739,000.00
N/A
Revenue This Year
$5.22
N/A
Revenue Next Year
$5.08
N/A
P/E Ratio
$21.38
★ N/A
Revenue Growth
★ 16.96
N/A
52 Week Low
$35.00
$22.30
52 Week High
$60.59
$47.65

Technical Indicators

Market Signals
Indicator
CAC
MLYS
Relative Strength Index (RSI) 37.87 41.01
Support Level $54.42 $22.36
Resistance Level $56.10 $31.19
Average True Range (ATR) 1.08 1.37
MACD -0.26 -0.43
Stochastic Oscillator 3.89 15.65

Price Performance

Historical Comparison
CAC
MLYS

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: